Myotonic Muscular Dystrophy Type 1
Overview
Myotonic muscular dystrophy (MMD) is a multisystem disorder that affects the brain, skeletal and smooth muscles, eyes, heart, gastrointestinal tract, lungs, and endocrine system. The 2 forms, type 1 and type 2, are caused by different gene mutations. Type 2 does not have a congenital or early childhood form and is not discussed further here. Type 1 can be classified into mild (late onset), classic (adult onset), childhood/juvenile, and congenital forms. The classification describes a continuum ranging from mild to severe disease, which generally correlates with trinucleotide repeat (CTG) length. MMD1 is a progressive condition; repeat expansion and RNA splicing dysregulation increases over time and leads to a gradual worsening in many domains including cognition, muscle strength, and others.Individuals with mild late adult onset may not develop symptoms until after 50 years old. [Ho: 2015] Classic "adult" onset often occurs after age 10 and involves progressive muscle weakness (often eventually requiring a wheelchair for mobility), cataracts, and cardiac conduction abnormalities. Children with childhood onset (before the age of 10, but after early infancy) often have similar symptoms and disease progression as those with congenital onset. Infants with congenital onset may present at birth with hypotonia, breathing or feeding problems, and drooling and/or swallowing problems. Global developmental delays are often observed in the first few years of life. Distal muscle atrophy and weakness, as well as the hallmark myotonia, may not be noted until school age or later. IQ may be borderline or low, learning disabilities may be present, and attention deficit hyperactivity disorder or characteristics of autism spectrum disorder are common. Management is currently supportive, incorporating regular surveillance and treatment of manifestations.
Other Names & Coding
DM*
Dystrophia myotonica
Myotonic dystrophy
Steinert disease
*Since "DM" could be interpreted as an abbreviation for diabetes mellitus, the abbreviation "MMD" will be used instead for myotonic muscular dystrophy.
G71.11, Myotonic muscular dystrophy
See ICD-10 for Myotonic Muscular Dystrophy (icd10data.com) for further coding details.
Prevalence
MMD is the most common muscular dystrophy. [Norwood: 2009] It affects an average of 1:2000 people in the United States. [Johnson: 2019] In most populations, type 1 appears to be more common than type 2, but prevalence varies in different ethnic populations and the founder effect may increase the prevalence in specific regions. [Theadom: 2014] [Pratte: 2015]Genetics
MMD results from a trinucleotide repeat (CTG) in the DMPK gene region on chromosome 19. It is one of the many examples of neurologic diseases, such as Huntington disease and fragile X syndrome, that are caused by an excessive number of such repeats (a CTG repeat length of 35 or more is abnormal). Children with congenital MMD often have >1000 repeats, though the congenital form may be seen with fewer repeats. In the case of MMD, these repeats are present in the RNA, but they are not translated into the protein. The disease mechanism for these untranslated repeats is called the “toxic RNA hypothesis.” In this disease model, the excessive CTG repeats bind RNA binding proteins important in splicing (editing) other RNAs besides DMPK. This leads to RNA splicing errors, which have been detected in many different proteins, in the brain (amyloid precursor protein), heart (troponin), muscle (chloride ion channel), and endocrine systems (insulin receptor). This could explain why MMD is a multisystemic disorder. [Wheeler: 2007]MMD is inherited in an autosomal dominant fashion. The disease-causing allele found in a parent with MMD may lengthen during the process of gametogenesis and the resulting offspring may have more severe disease and earlier onset than seen in the parent. This phenomenon is called anticipation. Anticipation resulting in large expansions (>1000 repeats), and hence congenital MMD, is much more common when the mother is the affected parent; anticipation with smaller or moderate expansions can occur from either parent. [Pratte: 2015] Myotonic Dystrophy Type 1 (GeneReviews) has further details related to genetics. [Bird: 1993]
Prognosis
Age of onset and severity of symptoms is variable. Mild presentation can involve cataracts and mild myotonia. Severe presentation can involve breathing issues, swallowing problems, or cardiac arrhythmias that are life-threatening. While there is no cure or treatment that slows progression of MMD, early intervention can reduce or eliminate some complications.Practice Guidelines
No authors listed.
A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management.
Neurology.
2020;94(9):414.
PubMed abstract
Johnson NE, Aldana EZ, Angeard N, Ashizawa T, Berggren KN, Marini-Bettolo C, Duong T, Ekström AB, Sansone V, Tian C, Hellerstein
L, Campbell C.
Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1.
Neurol Clin Pract.
2019;9(5):443-454.
PubMed abstract / Full Text
Roles of the Medical Home
At the time of diagnosis, the medical home should advise families regarding areas of uncertainty, such as clinical outcomes and the value of interventions as they pertain to both longevity and quality of life. Clinicians should explain the multisystem implications of this condition and help guide family decisions about monitoring and treating complications. [Kang: 2015]In addition, the medical home treats acute illness and performs well-child and chronic-care visits where progression of the condition and problems can be proactively managed. The medical home, with input from the family, should be the initiator and coordinator of visits to subspecialists unless a multidisciplinary Neuromuscular Clinic (see Neuromuscular Clinics (see NM providers [1])) is available. The goal is to avoid duplication of services or unnecessary appointments while still seeing the subspecialists needed. All screening and interventions are intended to promote growth and potential development, mitigate cumulative morbidities, optimize function, and limit mortality while maximizing quality of life. [Kang: 2015]
Clinical Assessment
Overview
It is easy to miss the diagnosis of MMD in babies unless the diagnosis is kept in mind when considering a child with respiratory and/or feeding problems, hypotonia, and/or global developmental delays without a family history of the disease. When the newborn or infant presents with these problems, assess the face of the mother (and father) for weakness, ptosis, and hollow temples. To further assess the parents, perform percussion myotonia testing on the tongue and thenar eminences. Have the parent close eyes and fists and hold them tightly for several minutes, then let go suddenly. Individuals with myotonia demonstrate a slow release. An electromyogram in the parent may also demonstrate myotonia associated with MMD if it is not clinically apparent.Pearls & Alerts for Assessment
MMD may present as global developmental delayIn a child with an uneventful birth, early MMD may present as global developmental delay. The characteristic myotonia is not present until later in childhood and the typical facial features may not be obvious unless the provider is aware of the potential for this underlying diagnosis in a child with developmental delays.
Complications with anesthesiaIndividuals with MMD, even those with only mild manifestations of the disease, have a higher rate of complications associated with general anesthesia. Families should be educated about this possibility and reminded of this during well-child visits. [Mangla: 2019].
Incidence of diabetesIndividuals with MMD may have insulin resistance that sometimes develops into diabetes, even in the absence of obesity.
Screening
Of Family Members
Since MMD1 can worsen in successive generations, the diagnosis of an infant with the congenital form may lead to the recognition of milder symptoms in parents and other relatives. It is important to screen at-risk relatives (e.g., siblings and parents) since early diagnosis allows treatment of complications, such as cardiac abnormalities or diabetes.For Complications
Depending on the individual's age and severity of MMD, screen for cataracts; early-onset cataracts are fairly common (posterior subcapsular/cortical type).MMD causes electrical problems in the heart, such as arrhythmias, atrial fibrillation, and conduction defects (less commonly cardiac muscle problems). Screen for cardiac problems yearly with an ECG at the minimum.
Screen for sensorineural hearing loss, which is present in more than half of individuals with DMD.
Children should have a sleep study at diagnosis or when new symptoms of daytime sleepiness occur to screen for sleep apnea. Sleep and fatigue are often reported as the most debilitating symptoms of MMD.
Presentations
Mild and classic presentations: Cataracts, cardiac arrhythmias, speech and swallowing problems, fatigue and sleep disorders (including central and obstructive sleep apnea), and early onset of type II diabetes may occur. Less severely affected children may be identified when they fail to meet early developmental milestones.Congenital/severe presentations: Babies with congenital MMD may be identified at birth with severe hypotonia, positional problems such as clubfeet or hip dysplasia, and breathing or swallowing problems. The latter 2 issues may be severe enough to require ventilation or tube feeding, sometimes for prolonged periods of time. Global developmental delays are often observed in the first few years of life. Distal muscle atrophy and weakness, as well as the hallmark myotonia, may not be noted until school age or later. IQ may be borderline or low, learning disabilities may be present, and attention deficit hyperactivity disorder or characteristics of autism spectrum disorder are common.
Diagnostic Criteria
Diagnosis is made by molecular testing confirming presence of the CTG repeat expansion in the DMPK gene of chromosome 19.Clinical Classification
For myotonic muscular dystrophy:- MMD1, the most common type, results from an abnormal DNA expansion (CTG) in the DMPK gene on chromosome 19 causing mis-splicing of mRNAs, affecting all organs of the body.
- MMD2 arises from an abnormal expansion of DNA (CCTG) in the first intron of CNBP (cellular nucleic acid binding protein). Note that unlike MMD1, where the number of repeats is roughly correlated with the severity of the disease, there is no correlation between phenotype and repeat length.
Differential Diagnosis
Differential diagnoses include many less common muscle and nerve diseases, such as distal muscular dystrophies and Dejerine Sottas disease (a type of hereditary motor sensory neuropathy with evidence that would be seen on EMG/NCV testing), and hyperkalemic periodic paralysis (which presents with episodic weakness).Because of the intellectual disability associated with MMD, diseases of the central nervous system may also be considered. Metabolic testing is normal in myotonic dystrophy. Although brain MRI is usually normal in individuals with MMD, it may show periventricular myelin changes that could be interpreted as evidence of perinatal hypoxic/ischemic injury. [Modoni: 2004] [Peglar: 2019]
Comorbid & Secondary Conditions
Increased rates of autism spectrum disorder, intellectual disability, and attention deficit hyperactivity disorder have been reported in this population. [Ekström: 2008] Diagnosis modules can be found at:History & Examination
Current & Past Medical History
Ask about a history of speech and swallowing problems, aspiration, frequent drooling, respiratory illnesses, fatigue, cardiac arrhythmia, palpitations, chest pain, dizziness, weakness, behavioral problems, learning delays in school, and diarrhea or constipation.Family History
Ask about a family history of early heart disease or pacemaker use, severe fatigue, early cataracts (before the age of 50), learning problems, and distal muscle weakness. Remember to examine the mother who may have undiagnosed MMD.Pregnancy/Perinatal History
Ask about a history of polyhydramnios and decreased fetal movements; prolonged or complicated labor; presence of developmental hip dysplasia and/or clubfeet; breathing and feeding problems near birth, including the inability to breast/bottle feed; difficulties learning to eat as an infant; failure to thrive.Developmental & Educational Progress
Determine when developmental milestones were achieved. Ask about IQ, learning disabilities, issues with attention, and any educational difficulties. Assess developmental and educational progress.Social & Family Functioning
Ask about family functioning. Identify resources to help families cope with a new diagnosis of MMD. Ask if the child has access to social and recreational outlets.Physical Exam
Growth Parameters
Ht | Wt - Children with MMD often have difficulty gaining and maintaining weight. Stature is typically normal in children with MMD.HEENT/Oral
Children with congenital MMD have facial muscle weakness that can cause a seemingly flattened affect, an upper lip that comes to a point (known as a tented upper lip), and a characteristically long face with hollowing at the temples. Ptosis may be present. Check for drooling, swallowing dysfunction, and cataracts. A high-arched palate may be noted. Adolescent males may have early balding at the temples.Testing
Sensory Testing
Ophthalmologic evaluation should be performed at diagnosis. Although cataracts are unusual in young children, strabismus and ptosis are common. Hearing problems are also common and hearing testing should also be performed at the time of diagnosis.Laboratory Testing
Children may have thyroid dysfunction and diabetes; consider annual screening with a TSH and HbA1c.Genetic Testing
Molecular genetic testing is available for diagnosis and is relatively inexpensive; it often obviates biopsy and electromyography.Other Testing
- Children with MMD require an ECG yearly to screen for progressive arrhythmias. Any detection of an early arrhythmia, most commonly first-degree heart block requires an urgent evaluation by a cardiologist.
- Consider a barium swallow study for symptoms of dysphagia or frequent pulmonary infections that may be due to silent aspiration.
- Perform a complete, age-appropriate, evaluation in all children. Initiate developmental therapies based on delays. Intellectual disability and other psychological symptoms are seen in more than half of children with congenital MMD. A neuropsychological profile may be helpful.
Specialty Collaborations & Other Services
Neuromuscular Clinics (see NM providers [1])
Referral to an MMD clinic for evaluation and genetic testing is recommended.
Pediatric Neurology (see NM providers [5])
If an MMD or other muscle disease clinic is not available, the child should be referred to pediatric neurology and/or genetics, depending on local expertise, for a baseline exam and periodic assessments as needed.
Medical Genetics (see NM providers [2])
A consultation is recommended to help with diagnosis and to help families understand genetic test results so they can make family-planning decisions. [Kang: 2015] If the family has further questions about the genetics of MMD, consider re-evaluation.
Pediatric Physical Medicine & Rehabilitation (see NM providers [3])
Consider a referral to evaluate development and recommend interventions aimed at increasing function.
Treatment & Management
Overview
Although children with myotonic dystrophy often seem to be doing fairly well, a survey performed in the US and Canada revealed that children with MMD are concerned about their problems communicating and with hand/finger problems. Parents were also concerned about their child’s communication but also noted that fatigue was a major problem in functioning on a daily basis. [Johnson: 2015] [Hagerman: 2019]Knockdown of the toxic repeat expansion may be possible using antisense oligonucleotides. There has been a prior clinical trial (NCT02312011) testing this approach. We would expect others will continue to improve on this approach in the near future. Gene therapy for myotonic dystrophy is likely still years away, but adeno-associated viral vector gene therapy is currently being worked on in the laboratory. [Crudele: 2019]
Pearls & Alerts for Treatment & Management
Complications with vecuronium and general anesthesiaChildren and adults with MMD are very slow to regain airway protection reflexes after anesthesia. If surgery is needed in a child with MMD, the anesthesiologist should be made aware of possible anesthetic complications.
Avoid statinsStatins may lead to increasing muscle weakness and pain.
Assess cardiac symptoms immediatelyAny symptoms suggestive of cardiac arrhythmia (e.g., chest pain with exertion, light-headedness, or palpitations) should be taken seriously.
Botox may cause worsening in targeted muscle groupsAvoid using neuromuscular blocking agents (e.g., botulinum toxin) in patients with MMD unless the contractures are determined to cause significantly greater impairment than would any potential worsening of weakness in the targeted muscle groups. [Kang: 2015]
FatigueParents of congenitally affected children from the United States and Canada report fatigue as an important problem for their children. Clinically, this is observed as older children who still need naps to function well. When fatigue or daytime sleepiness are present, consider a sleep study for obstructive or central sleep apnea. School accommodations may be necessary for children with fatigue. [Johnson: 2015]
How should common problems be managed differently in children with Myotonic Muscular Dystrophy Type 1?
Bacterial Infections
There is an increased risk for pneumonias in the setting of upper respiratory infections due to weakness of muscles required for optimal respiration.Prescription Medications
Care needs to be taken to begin any sedating medications at half the typical dose. These patients are sensitive to sedating medications and are at risk for associated respiratory depression. Any medication that prolongs the QT should be evaluated in the context of that patient's current ECG.Systems
Musculoskeletal
Specialty Collaborations & Other Services
Pediatric Neurology (see NM providers [5])
Depending on local availability, refer for periodic visits to monitor weakness.
Pediatric Orthopedics (see NM providers [6])
Consider a baseline visit with follow-up as necessary.
Neuromuscular Clinics (see NM providers [1])
Neurology follow-up may be available at specialized clinics.
Physical Therapy (see NM providers [12])
Refer for range-of-motion exercises, orthotic devices, heel cord lengthening procedures, or a combination of these interventions for children as needed. [Kang: 2015]
Development (general)
Specialty Collaborations & Other Services
Early Intervention for Children with Disabilities/Delays (see NM providers [35])
Early intervention programs for children 0 to 3 years of age are available in all states, but the services they offer may differ and supplemental therapies may be necessary.
Preschools (see NM providers [4])
If needed, instruct families to call their local school or school district office for enrollment information. If the child has been in Early Intervention, transition to preschool will be a part of the program.
Occupational Therapy (see NM providers [17])
Refer to enhance daily living activities, such as eating or dressing.
Pediatric Neurology (see NM providers [5])
Depending on local availability, refer for periodic visits to monitor developmental issues.
Mobility/Function/ADLs/Adaptive
Specialty Collaborations & Other Services
Pediatric Physical Medicine & Rehabilitation (see NM providers [3])
Consider referral for children with developmental delays and functional impairments.
Pediatric Orthopedics (see NM providers [6])
Children with joint contractures and/or scoliosis may be managed concurrently with pediatric orthopedics.
Physical Therapy (see NM providers [12])
Refer when help is needed for muscle strengthening, dealing with fatigue, or for a stander, walker, or wheelchair fitting.
Occupational Therapy (see NM providers [17])
Refer to help with functional impairments in carrying out activities of daily living.
Sleep
Sleep apnea (either central or obstructive), excessive leg movements, and dysregulation of rapid eye movement sleep may also contribute to fatigue in some children. If sleepiness, restless legs, or breathing abnormalities during sleep continue, consider referring to a sleep specialist. In more severe cases, stimulant medication or modafinil (Provigil) may be helpful. In younger children, a behavioral approach may help; the family should control bedtime and wake-up time and plan for scheduled naps. Consider suggesting a disability placard for the family's car to help with conserving the child's energy while out of the house; even if the child is only going to run around at a park, the child should conserve energy to get to the play area.
Specialty Collaborations & Other Services
Pediatric Sleep Medicine (see NM providers [0])
A consult may be helpful for children with suspected sleep problems including frequent awakening, snoring, and excessive daytime sleepiness. Therapies may include medications, adenoidectomy/tonsillectomy (by ENT), and/or CPAP.
Cardiology
Specialty Collaborations & Other Services
Pediatric Cardiology (see NM providers [2])
Clinicians should refer children with myotonic dystrophy for a baseline cardiac evaluation. The intervals of further evaluations should depend on the results of the baseline evaluation. [Kang: 2015] Exercise testing should be considered.
Respiratory
Specialty Collaborations & Other Services
Pediatric Pulmonology (see NM providers [4])
When available, refer to pulmonary or aerodigestive care teams that have experience managing the interface among oropharyngeal function, gastric reflux and dysmotility, nutrition, and respiratory systems and providing anticipatory guidance concerning trajectory, assessment modalities, complications, and potential interventions. [Kang: 2015]
Communication
Specialty Collaborations & Other Services
Speech - Language Pathologists (see NM providers [22])
Consider early referral for language assessment, delay, or augmentive speech methods such as sign language or speech devices.
Gastro-Intestinal & Bowel Function
Constipation/diarrhea: Most children with MMD experience constipation alternating with diarrhea. Constipation and diarrhea are easier to treat if caught early; bowel history should be part of every medical home visit. Dietary management with additions of fiber might be all that is necessary, but many children will need daily treatment with laxatives (PEG 3350, MiraLax, or GlycoLax). See the Portal's Constipation, Treatment & Management for treatment details.
Incontinence: Children may have prolonged urinary and fecal incontinence. A high-fiber diet may be helpful in reducing fecal urgency. If incontinence persists into the teenage years, a trial of anti-myotonia medication may be helpful.
Specialty Collaborations & Other Services
Pediatric Gastroenterology (see NM providers [3])
Consider a referral for constipation, reflux, and/or failure to gain adequate weight.
Nose/Throat/Mouth/Swallowing
Children with significant swallowing problems may need gastrostomy tube placement to allow efficient and safe liquid and/or food delivery. A gastrostomy tube may also be necessary for those children with severe failure to thrive, even if aspiration is not an obvious problem. In some children, placement of a feeding tube might be thought of as a temporary intervention so that the family may focus on the child and the quality of his or her eating without worrying constantly about the number of calories the child has received. In the child with gastroesophageal reflux disease and limited capacity to protect his or her airway, treatment with a Nissen fundoplication may be important. See Feeding Tubes & Gastrostomies in Children and Missing issue with id: 435a721.xml for more information.
Drooling: Many parents choose not to treat drooling due to concerns about the side effects of medication and surgery, but drooling in the socially aware older child can be very embarrassing and can create social barriers. Treatment possibilities include medications to decrease saliva, botulinum toxin treatments (temporary), or surgery to block salivary ducts. No known therapy helps oropharyngeal function. [Morgan: 2012] See Drooling in Children with Special Health Care Needs for resources and information about specific treatments.
Specialty Collaborations & Other Services
Pediatric Gastroenterology (see NM providers [3])
The medical home should order multidisciplinary evaluations with swallow therapists, gastroenterologists, and radiologists if there is evidence of failure to thrive or respiratory symptoms (or both). [Kang: 2015]
Pediatric Otolaryngology (see NM providers [8])
Children with drooling, excessive snoring, and/or swallowing problems may benefit from an assessment.
Speech - Language Pathologists (see NM providers [22])
Refer when there are swallowing problems, including drooling. Speech therapists may work with children with eating problems, depending on local expertise.
Nutrition/Growth/Bone
Specialty Collaborations & Other Services
Nutrition Assessment Services (see NM providers [0])
A visit with a nutritionist may be helpful for children with difficulty gaining weight.
Maturation/Sexual/Reproductive
Females with MMD should understand that their child has a 50/50 risk of being born with congenital MMD in a more severe form than the mother exhibits. Pregnancies of mothers with congenital MMD should be managed by a high-risk obstetrician, usually with birth planned for a tertiary care NICU. Labor may be prolonged, with increased risk of retained placenta and hemorrhage. The woman may have polyhydramnios, and she may note that fetal movements are decreased.
Specialty Collaborations & Other Services
Medical Genetics (see NM providers [2])
Genetic consultation is recommended to help with diagnosis and to help families understand genetic test results so they can make family-planning decisions. [Kang: 2015] Genetic counseling for teens with congenital MMD should be offered on a developmentally appropriate basis.
Endocrine/Metabolism
Specialty Collaborations & Other Services
Pediatric Endocrinology (see NM providers [4])
Refer if complications arise.
Mental Health/Behavior
Specialty Collaborations & Other Services
Therapy/Counseling > … (see NM providers [65])
Essential for management with CBT and, if needed, for treatment of depression and/or anxiety.
Developmental - Behavioral Pediatrics (see NM providers [2])
May be helpful if medications are needed for treatment of depression or anxiety.
Recreation & Leisure
Specialty Collaborations & Other Services
Physical Therapy (see NM providers [12])
A consultation can help with school and home adaptations (e.g., the child who wants a bike for a present, but the parents don't know what to purchase, or the child is interested in obtaining a sporting wheelchair).
Rec Centers, Parks, Zoos & Museums (see NM providers [10])
Appropriate choice of activities enhances physical benefits and helps reduce risk of social isolation.
Eyes/Vision
Specialty Collaborations & Other Services
Pediatric Ophthalmology (see NM providers [6])
Periodic visits starting at diagnosis are recommended.
Dental
Specialty Collaborations & Other Services
Pediatric Dentistry (see NM providers [6])
Pediatric dentists who have training in dealing with children with special health care needs may be necessary for some children.
General Dentistry (see NM providers [8])
Although they do not have formal training, dentists on this list have expressed an interest in treating children with special health care needs.
Surgery
Transitions
If necessary, apply for guardianship when the child turns 18. The often lengthy process usually includes psychological and medical evaluations and the involvement of a lawyer. At age 18, children in some states may become eligible for Medicaid or may qualify for resources with the Division of Services for People with Disabilities (DSPD) even if they were previously ineligible based on family income. Families may want to read Guardianship/Estate Planning for more information. Also, the Portal's Transition to Adulthood contains resources, checklists, and information about finding adult health care and insurance, guardianship and estate planning, living arrangements, and much more.
Issues Related to Myotonic Muscular Dystrophy Type 1
Ask the Specialist
How would you treat pain in children with MMD?
Often, pain is actually myotonia. Rather than traditional pain medications, consider trying anti-myotonia medications.
Do I need to do anything special before my patient has surgery?
Yes. A number of complications are associated with myotonic dystrophy and surgery. Please see the anesthesia guidelines available at Anesthesia & Myotonic Dystrophy - Risks & Recommendations (MDF).
My patient has significant diarrhea and constipation. What should I do?
The first line of treatment is a high-fiber diet for either diarrhea or constipation. Constipation may be refractory and require other laxatives.
Resources for Clinicians
On the Web
Myotonic Dystrophy Type 1 (GeneReviews)
Detailed information addressing clinical characteristics, diagnosis/testing, management, genetic counseling, and molecular
pathogenesis; from the University of Washington and the National Library of Medicine.
Myotonic Dystrophy (OMIM)
Information about clinical features, diagnosis, management, and molecular and population genetics; Online Mendelian Inheritance
in Man, authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
Learning about Myotonic Dystrophy (genome.gov)
Condition-specific information focused on the future of genomics research and genomic medicine; National Human Genome Research
Institute.
Myotonic Muscular Dystrophy Type 1 (Orphanet)
Overview of MMD1 (aka Steinert myotonic dystrophy) and links to more information, services, and other resources; from Orphanet,
a French-coordinated consortium involving over 40 countries to provide a portal for information about rare diseases and orphan
drugs.
Myotonic Muscular Dystrophy Type 2 (Orphanet)
Overview of MMD2 (aka proximal myotonic myopathy) and links to more information, services, and other resources; from Orphanet,
a French-coordinated consortium involving over 40 countries to provide a portal for information about rare diseases and orphan
drugs.
Helpful Articles
PubMed search for myotonic muscular dystrophy in children and adolescents, last 3 years
Ho G, Cardamone M, Farrar M.
Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.
World J Clin Pediatr.
2015;4(4):66-80.
PubMed abstract / Full Text
Ho G, Carey KA, Cardamone M, Farrar MA.
Myotonic dystrophy type 1: clinical manifestations in children and adolescents.
Arch Dis Child.
2018.
PubMed abstract
Johnson NE.
Myotonic Muscular Dystrophies.
Continuum (Minneap Minn).
2019;25(6):1682-1695.
PubMed abstract
Johnson NE, Abbott D, Cannon-Albright LA.
Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis.
Muscle Nerve.
2015;52(4):659-61.
PubMed abstract / Full Text
Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR.
Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.
Dev Med Child Neurol.
2015.
PubMed abstract / Full Text
Clinical Tools
Resources for Patients & Families
Answers to the common questions that parents may have about this condition. Provides links to other relevant high-quality websites.
Information on the Web
Myotonic Dystrophy (MedlinePlus)
Information for families that includes description, frequency, causes, inheritance, other names, and additional resources;
from the National Library of Medicine.
Facts about Myotonic Muscular Dystrophy (MDA)
Excellent overview of myotonic muscular dystrophy written for the family and patient; Muscular Dystrophy Association.
National & Local Support
Myotonic Dystrophy Support Group (MDSG)
This support organization offers information about myotonic dystrophy, events, research, and more.
Myotonic Dystrophy Foundation
A non-profit that provides adaptive equipment and emotional support to individuals and families affected by any of the neuromuscular
diseases.
Muscular Dystrophy Association
The Muscular Dystrophy Association (MDA) covers many conditions including CMT, Duchenne muscular dystrophy, and spinal muscular
atrophy. More information about these conditions, how to register, and clinic locations can be found here.
Studies/Registries
Clinical Trials in Myotonic type 1 (clinicaltrials.gov)
Studies looking at better understanding, diagnosing, and treating this condition; from the National Library of Medicine.
National Registry of Myotonic Dystrophy Patients (University of Rochester)
Accelerates research in myotonic dystrophy and FSH dystrophy by connecting patients with researchers, collecting longitudinal
data to track disease progression, and disseminating information to families, researchers, and care providers.
Myotonic Dystrophy Foundation Family Registry (PatientCrossroads)
Connects patients to researchers and allows patients to compare their symptoms with those of other patients.
Services for Patients & Families in New Mexico (NM)
| Service Categories | # of providers* in: | NM | NW | Other states (4) (show) | | NV | OH | RI | UT |
|---|---|---|---|---|---|---|---|---|---|
| Biochemical Genetics (Metabolics) | 1 | 1 | 2 | 1 | 3 | 3 | |||
| Developmental - Behavioral Pediatrics | 2 | 1 | 2 | 2 | 12 | 9 | |||
| Early Intervention for Children with Disabilities/Delays | 35 | 3 | 32 | 3 | 14 | 55 | |||
| General Dentistry | 8 | 1 | 25 | 1 | 34 | 132 | |||
| Medical Genetics | 2 | 1 | 5 | 1 | 4 | 6 | |||
| Neuromuscular Clinics | 1 | 1 | 2 | 1 | 3 | 5 | |||
| Nutrition Assessment Services | 3 | 1 | 2 | 7 | |||||
| Occupational Therapy | 17 | 1 | 27 | 2 | 19 | 39 | |||
| Pediatric Cardiology | 2 | 4 | 16 | 5 | |||||
| Pediatric Dentistry | 6 | 2 | 31 | 3 | 41 | 52 | |||
| Pediatric Endocrinology | 4 | 1 | 6 | 1 | 13 | 3 | |||
| Pediatric Gastroenterology | 3 | 1 | 6 | 1 | 19 | 4 | |||
| Pediatric Neurology | 5 | 5 | 17 | 5 | |||||
| Pediatric Ophthalmology | 6 | 1 | 6 | 1 | 8 | 5 | |||
| Pediatric Orthopedics | 6 | 4 | 8 | 4 | 16 | 21 | |||
| Pediatric Otolaryngology | 8 | 1 | 5 | 1 | 7 | 9 | |||
| Pediatric Physical Medicine & Rehabilitation | 3 | 3 | 3 | 3 | 6 | 14 | |||
| Pediatric Pulmonology | 4 | 4 | 8 | 4 | |||||
| Pediatric Sleep Medicine | 2 | 3 | |||||||
| Physical Therapy | 12 | 11 | 1 | 5 | 48 | ||||
| Preschools | 4 | 30 | 11 | 80 | |||||
| Rec Centers, Parks, Zoos & Museums | 10 | 3 | 80 | 3 | 21 | 71 | |||
| Speech - Language Pathologists | 22 | 4 | 13 | 4 | 31 | 70 | |||
| Therapy/Counseling | 65 | 23 | 362 | 23 | 132 | 669 | |||
For services not listed above, browse our Services categories or search our database.
* number of provider listings may vary by how states categorize services, whether providers are listed by organization or individual, how services are organized in the state, and other factors; Nationwide (NW) providers are generally limited to web-based services, provider locator services, and organizations that serve children from across the nation.
Bibliography
Bassez G, Lazarus A, Desguerre I, Varin J, Laforêt P, Bécane HM, Meune C, Arne-Bes MC, Ounnoughene Z, Radvanyi H, Eymard B,
Duboc D.
Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1.
Neurology.
2004;63(10):1939-41.
PubMed abstract
Bird TD.
Myotonic Dystrophy Type 1.
Gene Reviews.
1993.
PubMed abstract
Canavese F, Sussman MD.
Orthopaedic manifestations of congenital myotonic dystrophy during childhood and adolescence.
J Pediatr Orthop.
2009;29(2):208-13.
PubMed abstract
Crudele JM, Chamberlain JS.
AAV-based gene therapies for the muscular dystrophies.
Hum Mol Genet.
2019;28(R1):R102-R107.
PubMed abstract / Full Text
Ekström AB, Hakenäs-Plate L, Samuelsson L, Tulinius M, Wentz E.
Autism spectrum conditions in myotonic dystrophy type 1: a study on 57 individuals with congenital and childhood forms.
Am J Med Genet B Neuropsychiatr Genet.
2008;147B(6):918-26.
PubMed abstract
Engvall M, Sjögreen L, Kjellberg H, Robertson A, Sundell S, Kiliaridis S.
Oral health status in a group of children and adolescents with myotonic dystrophy type 1 over a 4-year period.
Int J Paediatr Dent.
2009;19(6):412-22.
PubMed abstract
Groh WJ.
Arrhythmias in the muscular dystrophies.
Heart Rhythm.
2012;9(11):1890-5.
PubMed abstract
Hagerman KA, Howe SJ, Heatwole CR.
The myotonic dystrophy experience: a North American cross-sectional study.
Muscle Nerve.
2019;59(4):457-464.
PubMed abstract / Full Text
Ho G, Cardamone M, Farrar M.
Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.
World J Clin Pediatr.
2015;4(4):66-80.
PubMed abstract / Full Text
Ho G, Carey KA, Cardamone M, Farrar MA.
Myotonic dystrophy type 1: clinical manifestations in children and adolescents.
Arch Dis Child.
2018.
PubMed abstract
Johnson NE.
Myotonic Muscular Dystrophies.
Continuum (Minneap Minn).
2019;25(6):1682-1695.
PubMed abstract
Johnson NE, Abbott D, Cannon-Albright LA.
Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis.
Muscle Nerve.
2015;52(4):659-61.
PubMed abstract / Full Text
Johnson NE, Aldana EZ, Angeard N, Ashizawa T, Berggren KN, Marini-Bettolo C, Duong T, Ekström AB, Sansone V, Tian C, Hellerstein
L, Campbell C.
Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1.
Neurol Clin Pract.
2019;9(5):443-454.
PubMed abstract / Full Text
Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR.
Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.
Dev Med Child Neurol.
2015.
PubMed abstract / Full Text
Kang PB, Morrison L, Iannaccone ST, Graham RJ, Bönnemann CG, Rutkowski A, Hornyak J, Wang CH, North K, Oskoui M, Getchius
TS, Cox JA, Hagen EE, Gronseth G, Griggs RC.
Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline
Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association
of Neuromuscular & Electrodiagnostic Medicine.
Neurology.
2015;84(13):1369-78.
PubMed abstract / Full Text
Endorsed by the American Academy of Pediatrics in March 2015.
Mangla C, Bais K, Yarmush J.
Myotonic Dystrophy and Anesthetic Challenges: A Case Report and Review.
Case Rep Anesthesiol.
2019;2019:4282305.
PubMed abstract / Full Text
Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C.
Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1.
Arch Neurol.
2004;61(12):1943-7.
PubMed abstract / Full Text
Morgan AT, Dodrill P, Ward EC.
Interventions for oropharyngeal dysphagia in children with neurological impairment.
Cochrane Database Syst Rev.
2012;10:CD009456.
PubMed abstract
No authors listed.
A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management.
Neurology.
2020;94(9):414.
PubMed abstract
Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V.
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.
Brain.
2009;132(Pt 11):3175-86.
PubMed abstract / Full Text
Peglar LM, Nagaraj UD, Tian C, Venkatesan C.
White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy.
Pediatr Neurol.
2019;96:64-69.
PubMed abstract
Pratte A, Prévost C, Puymirat J, Mathieu J.
Anticipation in myotonic dystrophy type 1 parents with small CTG expansions.
Am J Med Genet A.
2015;167A(4):708-14.
PubMed abstract
Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones K, Krishnamurthi R, Feigin V.
Prevalence of muscular dystrophies: a systematic literature review.
Neuroepidemiology.
2014;43(3-4):259-68.
PubMed abstract / Full Text
Wenninger S, Montagnese F, Schoser B.
Core Clinical Phenotypes in Myotonic Dystrophies.
Front Neurol.
2018;9:303.
PubMed abstract / Full Text
Wheeler TM, Thornton CA.
Myotonic dystrophy: RNA-mediated muscle disease.
Curr Opin Neurol.
2007;20(5):572-6.
PubMed abstract